Can You Get COVID-19 Again? Replay our May 22 HDLive!

Follow Our Live Coverage of COVID-19 Developments

About 360,000 ED Visits Were for Nonmedical Drug Abuse in 2016

More than half of estimated visits also involved nonpharmaceutical substances, including drugs, alcohol

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

WEDNESDAY, March 6, 2019 (HealthDay News) -- In 2016, there were an estimated 358,247 emergency department visits for harms from nonmedical use of pharmaceuticals, according to a study published online March 6 in the American Journal of Preventive Medicine.

Andrew I. Geller, M.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues collected data from the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project to calculate estimates of emergency department visits for harms from nonmedical use of pharmaceuticals.

The researchers estimated there were 358,247 emergency department visits for harms from nonmedical use of pharmaceuticals in 2016; 41.1 percent resulted in hospitalization. Overall, 50.9 percent of estimated visits involved patients aged ≤34 years. More than half of estimated visits (52.9 percent) also involved nonpharmaceutical substances, including illicit drugs and alcohol (34.1 and 21.8 percent, respectively). Benzodiazepines were implicated in 46.9 percent of estimated emergency department visits for nonmedical use of pharmaceuticals; in 6.5 percent of visits, they were the only substance implicated. Prescription opioids were implicated in 36.2 percent of visits and were the only substance implicated in 11.3 percent.

"Although opioids and benzodiazepines account for most nonmedical use visits, additional substances (licit and illicit) are often involved," the authors write. "Prescribing physicians should consider implementing specific screening to address polysubstance use and, when warranted, treatment interventions."

Abstract/Full Text

Last Updated: